Ovarian Cancer | Specialty

Role of PARP Inhibitors in Ovarian Cancer Continues to Evolve

February 6th 2015

For insight on the evolving role of PARP inhibitors in the treatment of ovarian cancer, OncLive interviewed Donna McNamara, MD, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC).

Dr. Donna McNamara on PARP Inhibitors for Ovarian Cancer Treatment

January 20th 2015

Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, talks about the benefits of PARP inhibitors for women with BRCA1 or BRCA2-mutated, platinum-sensitive ovarian cancer.

Grant Aims to Deliver First Stem-Cell Immunotherapy in Ovarian Cancer

January 19th 2015

The New York State Stem Cell Science Program recently awarded a 4-year $11.9 million grant to Roswell Park Cancer Institute to fund research and development of a stem-cell based treatment for ovarian cancer.

HIPEC for Ovarian Cancer: An Exciting Locoregional Strategy

January 13th 2015

Approximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.

BRCA Pioneer Offit Shares Insights on Evolving Testing Landscape

January 7th 2015

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

December 31st 2014

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

FDA Approves Olaparib for Advanced Ovarian Cancer

December 19th 2014

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.

The New BRCA1/2 Landscape

December 13th 2014

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.

Latest News & Insight: November 26, 2014

November 27th 2014

PARP Inhibitors for Breast and Ovarian Cancers

November 26th 2014

PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.

Challenges for the Future of Gynecologic Cancers

November 26th 2014

Emerging Therapies in Cervical Cancer

November 26th 2014

Bevacizumab in Recurrent Metastatic Cervical Cancer

November 26th 2014

Cervical Cancer Screening and Prevention

November 26th 2014

Promising Treatments in Ovarian Cancer

November 26th 2014

Bevacizumab in Ovarian Cancer

November 26th 2014

Platinum Resistance in Ovarian Cancer

November 26th 2014

CA-125 Testing in Ovarian Cancer

November 26th 2014

Intraperitoneal Chemotherapy in Ovarian Cancer

November 26th 2014

Antiangiogenic Agents in Ovarian Cancer

November 26th 2014